"New" molecular taxonomy in breast cancer

Clinical and Translational Oncology

Volumn 10, Issue 12, 2008, Pages 777-785

  Hergueta Redondo, Marta ^a   Palacios, José ^b   Cano, Amparo ^a   Moreno Bueno, Gema ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Basal; Breast cancer; Expression profile; HER2+; Luminal

Indexed keywords

BIOLOGICAL MODEL; BREAST TUMOR; CANCER STEM CELL; CLASSIFICATION; DIAGNOSTIC PROCEDURE; FEMALE; GENETIC HETEROGENEITY; GENETICS; HISTOLOGY; HUMAN; MAMMARY GLAND; METHODOLOGY; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; CLASSIFICATION; FEMALE; GENETIC HETEROGENEITY; HUMANS; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASTIC STEM CELLS;

EID: 60549096686     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0290-x     Document Type: Article

References (61)

1. American Cancer Society (2008) Cancer and figures. American Cancer Society
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717
3. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
4. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
5. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423
6. van 't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
7. Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398
8. Hu Z, Fan C, Oh DS et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96
9. Bertucci F, Finetti P, Rougemont J et al (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65:2170-2178
10. Calza S, Hall P, Auer G et al (2006) Intrinsic molecular signature of breast cancer in a populationbased cohort of 412 patients. Breast Cancer Res 8:R34
11. Kapp AV, Jeffrey SS, Langerod A et al (2006) Discovery and validation of breast cancer subtypes. BMC Genomics 7:231
12. Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65
13. McGee SF, Lanigan F, Gilligan E et al (2006). Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression. EMBO Rep 7:1084-1088
14. Gusterson BA, Ross DT, Heath VJ et al (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7:143-148
15. Liu S, Dontu G, Wicha MS (2005) Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7:86-95
16. Tavassoli F, Deville P (2003) World Health Organization: tumours of the breast and female genital organs (Who/IARC Classification of Tumours). IARC, Lyon
17. Elston CW, Ellis IO (1998) Assessment of histological grade. In Elston CW, Ellis IO (eds) The breast, Vol. 13. Churchill Livingstone, Edinburgh, New York, pp 356-384
18. Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25:2273-2284
19. Ross DT, Perou CM (2001) A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 17:99-109
20. Weigelt B, Peterse JL, van't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591-602
21. Gruvberger S, Ringner M, Chen Y et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984
22. Morris SR, Carey LA (2007) Gene expression profiling in breast cancer. Curr Opin Oncol 19: 547-551
23. Pusztai L, Mazouni C, Anderson K et al (2006) Molecular classification of breast cancer: limitations and potential. Oncologist 11:868-877
24. Hsu AL, Tang SL, Halgamuge SK (2003) An unsupervised hierarchical dynamic self-organizing approach to cancer class discovery and marker gene identification in microarray data. Bioinformatics 19:2131-2140
25. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108-118
26. Laakso M, Tanner M, Nilsson J et al (2006) Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12:4185-4191
27. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C (2007) The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19:552-557
28. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
29. Rakha EA, El-Syed ME, Green AR et al (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50:434-438
30. Jacquemier J, Padovani L, Rabayrol L et al (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207:260-268
31. Moinfar F (2008) Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology 75:119-131
32. Adélaïde J, Finetti P, Bekhouche I et al (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67:11565-11575
33. Melchor L, Benítez J (2008) An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 29:1475-1482
34. Adem C, Soderberg CL, Hafner K et al (2004) ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41:1-11
35. Chin K, DeVries S, Fridlyand J et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541
36. Herschkowitz JI, He X, Fan C et al (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10:R75
37. Varga Z, Zhao J, Ohlschlegel C et al (2004) Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44:332-338
38. Farmer P, Bonnefoi H, Becette V et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671
39. Ellis MJ, Tao Y, Young O et al (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019-3025
40. Marchiò C, Natrajan R, Shiu K et al (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399-407
41. Rodríguez-Pinilla SM, Rodríguez-Gil Y, Moreno-Bueno G et al (2007) Sporadic invasive breast carcinomas with medullary features display a basallike phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 31: 501-508
42. Sarrió D, Rodriguez-Pinilla SM, Hardisson D et al (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989-997
43. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
44. Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110:876-884
45. Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123-139
46. Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175-5180
47. Honrado E, Benítez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18:1305-1320
48. Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
49. Goldstein NS, Decker D, Severson D et al (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:1687-1696
50. Kim C, Bryant J, Horne Z et al (2005) Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94[Suppl 1]:S6 [abstract 46]
51. Nagata Y, Lan KH, Zhou XM et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
52. Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
53. Kauraniemi P, Kallioniemi A (2006) Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 13:39-49
54. Luck AA, Evans AJ, Green AR et al (2008) The in fluence of basal phenotype on the metastatic pat tern of breast cancer. Clin Oncol (R Coll Radiol) 20:40-45
55. Rodríguez-Pinilla SM, Sarrió D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12: 1533-1539
56. Rodríguez-Pinilla SM, Sarrió D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12: 1533-1539
57. Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518-524
58. Fulford LG, Reis-Filho JS, Ryder K et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9:R4
59. Visvader JE, Lindeman GJ (2006) Mammary stem cells and mammopoiesis. Cancer Res 66:9798-9801
60. Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197
61. Smalley M, Ashworth A (2003) Stem cells and bre ast cancer: a field in transit. Natl Rev Cancer 3:832-844